{
    "clinical_study": {
        "@rank": "16628", 
        "arm_group": [
            {
                "arm_group_label": "AMG 334 Treatment A", 
                "arm_group_type": "Active Comparator", 
                "description": "Single dose level administered via SC in female subjects with hot flashes associated with menopause."
            }, 
            {
                "arm_group_label": "AMG 334 Treatment B", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single dose level administered via SC in female subjects with hot flashes associated with menopause."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, stratified, double-blind, placebo-controlled, parallel-group study in\n      female subjects with HFs associated with menopause. This study will evaluate the efficacy of\n      AMG 334 as measured by reduction from baseline in the frequency and severity of daily HFs at\n      weeks 2, 4, 8, 12, and 16 after a single dose of AMG 334."
        }, 
        "brief_title": "Randomized, Parallel-group, Double-blind, Placebo-controlled, Study to AMG 334 in Women With Hot Flashes", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Vasomotor Symptoms; Hot Flashes", 
        "condition_browse": {
            "mesh_term": "Hot Flashes"
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, stratified, double-blind, placebo-controlled, parallel-group study in\n      female subjects with HFs associated with menopause. This study will evaluate the efficacy of\n      AMG 334 as measured by reduction from baseline in the frequency and severity of daily HFs at\n      weeks 2, 4, 8, 12, and 16 after a single dose of AMG 334.\n\n      Study Phase: 1b\n\n      Primary Objective:\n\n      To evaluate the frequency of moderate to severe daily HFs at week 4 after a single dose of\n      AMG 334 in female subjects with HFs associated with menopause.\n\n      Secondary Objectives:\n\n      To evaluate changes in the severity of daily HFs at week 4 after a single dose of AMG 334 in\n      female subjects with moderate to severe HFs associated with menopause.\n\n      To evaluate the safety, tolerability, and immunogenicity of AMG 334 in female subjects with\n      HFs associated with menopause\n\n      To characterize the pharmacokinetic (PK) profile of AMG 334 after a single subcutaneous (SC)\n      dose in female subjects with HFs associated with menopause\n\n      Hypotheses:\n\n      This study will test the hypothesis that the vasodilation associated with capsaicin-induced\n      dermal blood flow (DBF) provides a good model for the vasodilation associated with HFs;\n      therefore AMG 334 doses that cause DBF inhibition will be safe and well tolerated, and will\n      be effective in the reduction of the frequency and/or severity of HFs."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  female subjects with hot flashes associated with menopause between 45 and 65 years of\n             age, inclusive, with no history or evidence of clinically relevant medical disorders\n             as determined by the investigator in consultation with the Amgen physician.\n\n        Exclusion Criteria:\n\n          -  History or evidence of clinically significant disorder (including psychiatric),\n             condition or disease that, in the opinion of the Investigator or Amgen physician\n             would pose a risk to subject safety or interfere with the study evaluation,\n             procedures, or completion."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "103", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01890109", 
            "org_study_id": "20120180"
        }, 
        "intervention": [
            {
                "arm_group_label": "AMG 334 Treatment A", 
                "description": "Single dose level administered via SC in female subjects with hot flashes associated with menopause.", 
                "intervention_name": "AMG 334", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AMG 334 Treatment B", 
                "description": "Single dose level administered via SC in female subjects with hot flashes associated with menopause", 
                "intervention_name": "AMG 334", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Vasomotor symptoms; Hot Flashes", 
        "lastchanged_date": "May 15, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92108"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33186"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27103"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19114"
                    }, 
                    "name": "Eugene Andruczyk"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19114"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mt. Pleasant", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29464"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98105"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Stratified, Parallel-group, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 334 in Women With Hot Flashes Associated With Menopause", 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The 4-week endpoint frequency is defined as the average hot flash frequency over 7 days between weeks 3 and 4", 
            "measure": "Ratio of week 4 to baseline frequency of moderate to severe daily HFs", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01890109"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Ratio of week 4 to baseline daily hot flash severity score", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Number of treatment emergent adverse events per subject", 
                "safety_issue": "Yes", 
                "time_frame": "16 weels"
            }, 
            {
                "measure": "The maximum observed concentration after a single dose of AMG 334", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "The number of subjects with anti-AMG 334 antibodies after a single dose of AMG 334", 
                "safety_issue": "Yes", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "The time to maximum concentration after a single dose of AMG 334", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "The area under the serum-concentration curve after a single dose of AMG 334", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}